Pediatrix Medical Group Beheer
Beheer criteriumcontroles 3/4
De CEO Pediatrix Medical Group is Jim Swift, benoemd in Jan2023, heeft een ambtstermijn van 1.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.24M, bestaande uit 29% salaris en 71% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.2% van de aandelen van het bedrijf, ter waarde $ 2.73M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.1 jaar en 4.3 jaar.
Belangrijke informatie
Jim Swift
Algemeen directeur
US$2.2m
Totale compensatie
| Percentage CEO-salaris | 29.0% |
| Dienstverband CEO | 1.8yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 2.1yrs |
| Gemiddelde ambtstermijn bestuur | 4.3yrs |
Recente managementupdates
Recent updates
Pediatrix Medical Group, Inc. (NYSE:MD) Shares Fly 27% But Investors Aren't Buying For Growth
Nov 06
Here's Why Pediatrix Medical Group (NYSE:MD) Has A Meaningful Debt Burden
Oct 19We Like These Underlying Return On Capital Trends At Pediatrix Medical Group (NYSE:MD)
Sep 28Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified
Aug 07Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger
May 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking
Mar 29Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors
Dec 25Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?
Oct 13Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold
Aug 08At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?
Jul 03The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing
Jun 08Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?
Feb 20Pediatrix Medical Group Q4 2022 Earnings Preview
Feb 16Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold
Dec 22Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing
Dec 20Pediatrix appoints James Swift as chief executive officer
Dec 15Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Nov 05Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M
Nov 03Pediatrix: These 5 Graphs Suggest It's A Buy
Sep 29Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly
Sep 13Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return
Aug 29Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Jul 27Pediatrix: Seeking 46% Return Objective As Speculative Buy
Jul 14MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jun 24MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet
May 25Return Trends At MEDNAX (NYSE:MD) Aren't Appealing
Apr 20MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 08MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly
Feb 15Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital
Jan 19Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$254m |
| Jun 30 2024 | n/a | n/a | -US$252m |
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$2m | US$650k | -US$60m |
| Sep 30 2023 | n/a | n/a | US$88m |
| Jun 30 2023 | n/a | n/a | US$95m |
| Mar 31 2023 | n/a | n/a | US$98m |
| Dec 31 2022 | US$1m | US$450k | US$63m |
Compensatie versus markt: De totale vergoeding ($USD 2.24M ) Jim } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.36M ).
Compensatie versus inkomsten: De vergoeding van Jim is gestegen terwijl het bedrijf verliesgevend is.
CEO
Jim Swift (62 yo)
1.8yrs
Tenure
US$2,237,839
Compensatie
Dr. James D. Swift, M.D., also known as Jim, is Director of Brave Care, Inc. since October 2021. He had been the Chief Operating Officer at Pediatrix Medical Group, Inc. since May 2022 until December 31, 2...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$2.24m | 0.20% $ 2.7m | |
| Chief Administrative Officer | 2.1yrs | US$1.83m | 0.19% $ 2.6m | |
| Executive VP | less than a year | geen gegevens | 0.052% $ 701.9k | |
| Senior VP & Chief Accounting Officer | 8.5yrs | US$1.43m | geen gegevens | |
| Senior VP & Chief Information Officer | 2.8yrs | geen gegevens | geen gegevens | |
| Senior VP of Finance | no data | geen gegevens | geen gegevens | |
| Senior VP | 3.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of People Services | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Administration & Managed Care | no data | geen gegevens | geen gegevens | |
| President of Regional Operations (Central) | no data | geen gegevens | geen gegevens | |
| President of Regional Operations (South-Central) | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Operations | no data | geen gegevens | geen gegevens |
2.1yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van MD wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$2.24m | 0.20% $ 2.7m | |
| Chair | 4.3yrs | US$554.45k | 0.20% $ 2.7m | |
| Lead Independent Director | 4.3yrs | US$295.00k | 0.081% $ 1.1m | |
| Independent Director | 4.3yrs | US$252.50k | 0.065% $ 876.5k | |
| Independent Director | 1.5yrs | US$201.00k | 0.035% $ 468.3k | |
| Independent Director | 4.3yrs | US$230.00k | 0.065% $ 876.4k | |
| Independent Director | 4.3yrs | US$245.00k | 0.043% $ 577.8k | |
| Board Observer | 4.3yrs | geen gegevens | geen gegevens | |
| Independent Director | 5.5yrs | US$242.50k | 0.069% $ 932.8k | |
| Independent Director | 2.5yrs | US$230.00k | 0.023% $ 312.0k |
4.3yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van MD wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).